Phase II and pharmacogenetic study of docetaxel (D) and capecitabine (C) in chemonaive non-small cell lung cancer (NSCLC) patients (pts)
Lustberg M, Bekaii-Saab T, Diasio R, Ezzeldin H, Starrett S, Otterson G, Villalona M. Phase II and pharmacogenetic study of docetaxel (D) and capecitabine (C) in chemonaive non-small cell lung cancer (NSCLC) patients (pts). Journal Of Clinical Oncology 2008, 26: 19090-19090. DOI: 10.1200/jco.2008.26.15_suppl.19090.Peer-Reviewed Original ResearchNon-small cell lung cancer patientsCell lung cancer patientsLung cancer patientsCancer patientsPharmacogenetic studiesPhase IICapecitabinePatientsDocetaxel